Theralase Releases Q12021 Interim Financial Statements
28 mai 2021 18h58 HE
|
Theralase Technologies Inc.
TORONTO, May 28, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
IMAGIN MEDICAL REPORTS MANUFACTURING PROGESS
16 mars 2021 08h05 HE
|
Imagin Medical Inc.
VANCOUVER, B.C. / BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”)...
IMAGIN MEDICAL CLOSES SECOND TRANCHE OF CONVERTIBLE NOTE OFFERING
18 févr. 2021 08h30 HE
|
Imagin Medical Inc.
Vancouver, B.C. and Boston, MA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) (“Imagin” or the...
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
27 janv. 2021 20h30 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
Imagin Medical Engages Torrey Hills Capital
20 janv. 2021 08h30 HE
|
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (FSE: DPD2) ("Imagin" or the "Company") is pleased to...
Imagin Medical Builds Momentum for 2021
13 janv. 2021 08h30 HE
|
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical (CSE: IME) (OTC: IMEXF) (FRA: DPD2) (the “Company”) announces that critical milestones...
InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)
13 janv. 2021 08h30 HE
|
InvestorBrandNetwork (IBN)
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing...
New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting
02 déc. 2020 10h03 HE
|
FerGene Inc.
CAMBRIDGE, Mass, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Low rate of cystectomy and delayed time to cystectomy among patients who achieved complete responsePatient characteristics or prior treatment...
Global Disposable Incontinence Products Market Is Expected to Reach USD 18.59 billion by 2027 : Fior Markets
12 oct. 2020 22h00 HE
|
Fior Markets
Newark, NJ, Oct. 12, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global disposable incontinence products market is expected to grow from USD 10.42 billion in 2019 and...
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
24 mars 2020 08h00 HE
|
Aravive, Inc.
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...